The development of covalent, allele-specific inhibitors of KRASG12C represents a major breakthrough in precision oncology. Herein we discuss recent data from the phase II KRYSTAL-1 trial of adagrasib in KRASG12C-mutated non-small-cell lung cancer (NSCLC). This trial showed responses in a subset of patients, including among those with brain metastases, and offers exploratory insights into potential biomarkers of response.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).
Lito, P., Solomon, M., Li, L.-S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351, 604–608 (2016).
Hong, D. S. et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207–1217 (2020).
Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381 (2021).
Jänne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N. Engl. J. Med. 387, 120–131 (2022).
Ou, S. I. et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumours (KRYSTAL-1). J. Clin. Oncol. https://doi.org/gqd4bm (2022).
Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679–683 (2021).
Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382–2393 (2021).
Xue, J. Y. et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature 577, 421–425 (2020).
Sabari, J. K. et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer. Clin. Cancer Res. https://doi.org/h6w9 (2022).
Acknowledgements
Y.R.M-G. has received a Kristina M. Day Young Investigator Award from Conquer Cancer, the ASCO Foundation (endowed by C.M. Baum and C.A. Baum), and has received training through an institutional K30 grant from the NIH (CTSA UL1TR00457). P.L. receives support in part from the Damon Runyon Cancer Research Foundation, NIH NCI (grants 1R01CA23074501 and 1R01CA23026701A1), the Pershing Square Sohn Cancer Research Alliance and The Pew Charitable Trusts. This work is supported by the NIH/NCI Cancer Center Support Grant (P30 CA008748) to Memorial Sloan Kettering Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Y.R.M-G. has received support for travel, accommodation and expenses from AstraZeneca, honoraria from Virology Education and Projects in Knowledge (for a program funded by an educational grant from Amgen) and acknowledges associated institutional research support funded by Elucida Oncology, Endeavor Biomedicines, Hengrui USA/Jiangsu Hengrui Pharmaceuticals, Loxo Oncology at Eli Lilly, Luzsana Biotechnology and Taiho Oncology and royalties from Rutgers University Press and Wolters Kluwer. P.L. is listed as an inventor on patents filed by MSKCC on the treatment of cancers with BRAF or KRAS mutations. P.L. receives institutional research support funded by Amgen, Boehringer Ingelheim, Mirati, Revolution Medicines and Virtec Pharmaceuticals, consulting fees or honoraria from AmMax Bio, Black Diamond Therapeutics, Boehringer Ingelheim, Repare Therapeutics and Revolution Medicines and is a member of the scientific advisory board for Frontier Medicines.
Rights and permissions
About this article
Cite this article
Murciano-Goroff, Y.R., Lito, P. The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer. Nat Rev Clin Oncol 19, 677–678 (2022). https://doi.org/10.1038/s41571-022-00676-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00676-4
This article is cited by
-
Adagrasib: First Approval
Drugs (2023)